Clinical Study
Efficacy of Levofloxacin Based Triple and High-Dose PPI-Amoxicillin Dual Eradication Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies
Table 3
Adverse events of the third-line eradication therapy.
| ||||||||||||||||||||||||||||
RAL group: RPZ 10 mg (b.i.d.), AMPC 750 mg (b.i.d.), and LVFX 500 mg (o.d.). ‡RA group: RPZ 10 mg (q.i.d.) and AMPC 500 mg (q.i.d.). ∗Chi-square test. |